

Title: Polygenic risk score in post-mortem diagnosed sporadic early onset Alzheimer's disease

Authors: Sultan Chaudhury¹, Tulsi Patel¹, Imelda S. Barber¹, Tamar Guetta-Baranes¹, Keeley J. Brookes¹, Sally Chappell¹, James Turton¹, Rita Guerreiro^{2,3,4}, Jose Bras^{2,3,4}, Dena Hernandez⁵, Andrew Singleton⁵, John Hardy^{2,4}, David Mann⁶, ARUK Consortium and Kevin Morgan¹.

1. Human Genetics Group, University of Nottingham, Nottingham, UK.
2. Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
3. Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, Aveiro, Portugal
4. UK Dementia Research Institute at UCL (UK DRI), London, UK.
5. Laboratory of Neurogenetics, National Institute of Aging, National Institute of Health, Bethesda, MD, USA.
6. Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK.

Abstract

Sporadic early onset Alzheimer's disease (sEOAD) exhibits the symptoms of late onset Alzheimer's disease (LOAD) but lacks the familial aspect of the early onset familial form. The genetics of Alzheimer's disease (AD) identifies *APOE*ε4 to be the greatest risk factor; however, it is a complex disease involving both environmental risk factors and multiple genetic loci. Polygenic risk scores (PRS) accumulate the total risk of a phenotype in an individual based on variants present in their genome. We determined whether sEOAD cases had a higher PRS compared to controls. A cohort of sEOAD cases were genotyped on the NeuroX array and PRS were generated using PRSice. The target dataset consisted of 408 sEOAD cases and 436 controls. The base dataset was collated by the IGAP consortium, with association data from 17,008 LOAD cases and 37,154 controls, which can be used for identifying sEOAD cases due to having shared phenotype. PRS were generated using all common SNPs between the base and target dataset, PRS were also generated using only SNPs within a 500kb region surrounding the *APOE* gene. Sex and number of *APOE* ε2 or ε4 alleles were used as variables for logistic regression and combined with PRS. The results show that PRS is higher on average in sEOAD cases than controls, although there is still overlap amongst the whole cohort. Predictive ability of identifying cases and controls using PRSice was calculated with 72.9% accuracy, greater than the *APOE* locus alone (65.2%). Predictive ability was further improved with logistic regression, identifying cases and controls with 75.5% accuracy.

1.0 Introduction

Alzheimer's disease (AD) is the most common form of dementia, characterised by the deterioration of memory, language, visuospatial skills, and behaviour (Budson and Kowall, 2011). Dementia currently affects an estimated 46.8m people globally (Prince et al., 2015). Hallmarks of AD were originally identified post-mortem from histopathological signs of neuritic plaques, composed of amyloid- β , and neurofibrillary tangle formation; post-mortem examination of brain tissue for these hallmarks remains the most definitive diagnosis of AD. Clinical diagnosis is accurately verified in more than 85% of cases (Naj and Schellenberg, 2016).

AD can be categorised based on age of onset, where presentation of symptoms in individuals before the age of 65 are classified as early-onset Alzheimer's disease (EOAD), whilst late onset (LOAD) classifies individuals with onset over 65 (Barber et al., 2017; Wingo et al., 2012). LOAD has a heritability estimated to be around 70%, lower than estimates of heritability for EOAD, which vary between 80-100% (Barber et al., 2017; Wingo et al., 2012). An estimated 10% of EOAD cases have a familial aspect and are subsequently classified as early-onset familial AD (EOFAD). Autosomal dominant variants in the genes Amyloid precursor protein (*APP*), Presenilin 1 (*PSEN1*) and Presenilin 2 (*PSEN2*) have been discovered to increase amyloid- β production, increasing risk of EOFAD (Liu, C. et al., 2013; Wingo et al., 2012). The remainder of early-onset cases, classed as sporadic (sEOAD), are thought to be predominantly polygenic. The accumulation of variants which independently increase risk of LOAD may lead to sEOAD at an earlier stage of life (Barber et al., 2017; Wingo et al., 2012).

The association of the *APOE* gene has been the most consistent observation in AD genetics with the presence of an *APOE* $\epsilon 4$ allele significantly more common amongst individuals diagnosed with AD, whilst the $\epsilon 2$ allele is considered protective (Liu, C. et al., 2013; Naj and Schellenberg, 2016). Through genome wide association studies (GWAS), around 20 genetic loci had been discovered, which affect risk of LOAD (Lambert et al., 2013). Follow-up studies based on the GWAS have identified other potential candidate genes AD risk genes not previously identified, including the *TRIP4*, *SPPL2A* genes (Ruiz et al., 2014), and *ABI3* gene (Sims et al., 2017). Next-generation sequencing (NGS) has also enabled the identification of rare variants, one of the most consistent being the R47H variant in the *TREM2* gene locus (Guerreiro et al., 2013; Jonsson et al., 2013) which affect risk of AD previously not identified in GWAS (Giri et al., 2016; Lambert et al., 2013; Naj and Schellenberg, 2016). Although most studies utilise Caucasian populations, further risk variants have been identified through NGS in African American individuals within the gene *AKAP9* (Giri et al., 2016; Logue et al., 2014). Conversely protective variants have also been identified including a small coding deletion (rs10553596) within the *CASP7* gene associated with reduced incidence of AD amongst individuals with the *APOE* $\epsilon 4\epsilon 4$ genotype in four independent imputed datasets (Ayers et al., 2016). Further protective rare variants have also been identified by imputation of previous datasets such as the *PLCG2* gene (Sims et al., 2017).

Following on from these studies Marden and colleagues (Marden et al. 2014, Marden et al. 2016) sought to determine if a summative analysis of GWAS variants would be able to predict a dementia probability score. An AD genetic risk score (AD-GRS) was calculated by multiplying each individual GWAS allele effect size using the beta coefficients obtained from a previous dataset. This type of analysis demonstrated that AD-GRS could predict LOAD phenotype (Verhaaren et al. 2013, Slegers et al. 2015, Xiao et al. 2015, Yokoyama et al. 2015, Chouraki et al. 2016, Desikan et al. 2017), MCI conversion to LOAD (Rodriguez-Rodriguez et al. 2013, Adams et al. 2015), hippocampal cortical thickness (Sabuncu et al. 2012, Harrison et al. 2016), hippocampal volume (Lupton et al. 2016), CFS biomarkers (Martiskainen et al. 2015), and plasma inflammatory biomarkers (Morgan et al. 2017).

This approach has been expanded to include further polymorphisms of smaller but important effect sizes to develop a polygenic risk score (PRS) (Eusden *et al.* 2015). This is an improvement on previous tests as they do not perform well when non-associated SNPs are included (Chapman and Whittaker 2008, Basu *et al.* 2011) and is considered to find SNPs of disease relevance that have too small an effect size to be identified conventionally (Pan *et al.* 2015).

In a recent study, polygenic scores were calculated for a cohort of LOAD cases and controls: the study used genotype information of the cohort to identify common variants that affect the risk of developing AD and used polygenic scores to form a risk prediction model (Escott-Price *et al.*, 2015). By producing a model which identifies individuals with a high polygenic risk score, the potential for early screening, diagnosis and determination of disease severity becomes possible (Eusden, *et al.*, 2015).

In this study we have used genotype information generated on the NeuroX chip to generate a PRS in sEOAD. The NeuroX is a customised genotyping array built on the foundation of the Infinium HumanExome BeadChip v1.1, with additional custom content. The array is designed to collect genotype information at markers across the entire genome. The HumanExome BeadChip foundation is made up of 242,901 markers, identifying variants in a series of metabolic, cancerous, diabetic, and psychiatric disorders (Barber *et al.*, 2017; Nalls *et al.*, 2015). The custom content includes 24,706 markers from candidate loci associated with neurological diseases such as AD, Frontotemporal Dementia, Parkinson's Disease, Multiple System Atrophy, Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Charcot Marie Tooth, and Progressive Supranuclear Palsy (Nalls *et al.*, 2015).

To calculate a PRS we have used the software package, PRSice, which utilises genotype information from individuals in a target dataset based on the effect scores of single nucleotide polymorphisms (SNPs) from a second dataset, termed the base dataset. The program uses R to define parameters and PLINK for the computational analysis (Purcell *et al.*, 2007; R Core Team, 2013). PRSice is a command line program that allows specific parameters to be considered when generating PRS. The output files of the analysis include a list of individuals' scores at the best-fit threshold for predicting disease risk and a list of each tested threshold with its corresponding Nagelkerke's R^2 value, quantifying the level of predictability using that threshold (Eusden *et al.*, 2015).

Linkage disequilibrium (LD) is a common problem when SNPs are scored based on their weighted effect and frequency when comparing cases and controls of a disease. The alleles of two SNPs present on the same chromosome can be commonly inherited together, and the recurrence of particular alleles at loci are an indicator of the degree of LD between SNPs (Bush and Moore, 2012). Given two SNPs in tight LD, both could be perceived as contributing to the disease risk in a functional haplotype, however it may be that only one polymorphism is responsible for the phenotypic effect.

The aim of this study was to genotype sEOAD cases and controls to generate a PRS based on the genotype information of SNPs identified, and then using the estimated cumulative effect size the SNPs have on disease risk, to determine the predictability of the PRS at predicting cases vs controls.

2.0 Methods

2.1 Samples

The cohort genotyped consisted of 451 sEOAD cases (48.6% female) and 528 controls (51.3% female). sEOAD cases were screened for known disease causing variants within exons 16 and 17 of *APP* as well as variants in genes *PSEN1* and *PSEN2* to minimise inclusion of EOFAD cases. The diseased individuals had a documented or predicted age of onset of ≤ 65 years. Diagnosis of definite or probable sEOAD had met guidelines set by the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS), the Alzheimer's disease and Related Disorders Association (ADRDA) and the Consortium to Establish a Registry for Alzheimer's disease (CERAD). APOE ϵ status was determined for all individuals. At least one APOE $\epsilon 4$ allele was present in 57.6% of cases, with 22.3% of which being homozygotes ($n=58$); 22.7% of controls harboured at least one $\epsilon 4$ allele, seven control samples were $\epsilon 4$ homozygotes. These samples are described in greater detail in the paper by Barber *et al.* (2017). Full details of the samples used in this study are outlined in Table 1. Experimental procedures were completed with informed consent, with approval from local ethics committee (Nottingham Research Ethics Committee 2 (REC reference 04/Q2404/130) and completed in accordance with approved guidelines. A standard phenol chloroform DNA extraction method was used on 2mls of blood or 100mgs of brain tissue. DNA quality was assessed using gel electrophoresis and quantity was determined by NanoDrop 3300 spectrometry (Barber *et al.*, 2017).

2.2 NeuroX array

Clustering and the first stage of Quality Control (QC) was completed in Illumina GenomeStudio 2011.1. GenomeStudio took raw fluorescent signal results and formed clusters of the individual genotypes for each SNP. A cluster file, provided by the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE), was used to assist in forming the cluster boundaries for most SNPs present on the chip and the remaining SNPs are allocated automatically by the program (Barber *et al.*, 2017).

The SNPs were assessed on how well clusters formed in GenomeStudio: clusters are expected to localise at single points with high intensity, to form in certain locations based on the allele present and whether the genotype is heterozygous, not form too close to one another, and to not be too wide or elliptical. SNPs were grouped into each non-autosomal chromosome whilst all autosomal SNPs were assessed together. Clustering of SNPs in genes of interest such as *APOE* were also assessed (Barber *et al.*, 2017).

Once QC was completed for clustering, the resulting dataset underwent final QC, SNPs and individuals were assessed using PLINK (Purcell *et al.*, 2007). Individuals with a sample call rate below 95% were removed, likely as a result of poor DNA quality, as well as SNPs with a call rate below 90% as that could be due to probe design issues. PLINK was used to calculate ancestry information, Hardy-Weinberg equilibrium, relatedness, and heterozygosity (Barber *et al.*, 2017). Adherence to Hardy-Weinberg equilibrium (HWE) was identified and SNPs which did not meet HWE ($P < 1.2E-06$) were removed. Individuals sharing more than 18.75% identity by state (equivalent to second or third cousins) were removed to distinguish between relatives with atypical heterozygosity and outliers in populations. Individuals with a heterozygosity greater than or less than three times the standard deviation were removed as indicators of cross-contamination or inbreeding respectively. Univariate logistic regression was performed where the outcome variable was disease status (case vs control) and all SNPs with a P-value below this corrected threshold were removed. The final target dataset

contained genotype information for 265,049 SNPs of 408 cases (48.0% female) and 436 controls (58.6% female) (Barber *et al.*, 2017).

2.3 Polygenic Risk Scoring

PRS calculated using PRSice required SNP information (SNP coordinate, affected allele, reference allele, P-value, and effect size as either odds ratio or θ) from an independent cohort, to act as a base dataset (Eusden *et al.*, 2015). The base dataset was collated by the International Genomics of Alzheimer's Project (IGAP) consortium, with association data for 7,055,881 SNPs from 17,008 LOAD cases and 37,154 controls. The data was accumulated as a meta-analysis of genome wide association studies performed by Genetic and Environmental Risk for Alzheimer's Disease (GERAD), European Alzheimer's Disease Initiative (EADI), Cohorts for Heart and Ageing Research in Genomic Epidemiology (CHARGE), and Alzheimer's Disease Genetics Consortium (ADGC) (Lambert *et al.*, 2013). There is no equivalent data to this available for sEOAD due to the lower frequency of the disease and its diagnosis, however the shared phenotype between the two forms of AD may be caused by variants which affect risk of developing AD common to both LOAD and sEOAD.

PRSice initially identified all SNPs common between the base and target dataset; PRS were calculated by ordering all SNPs in the base dataset by association tested P-value; SNPs present within the P-value threshold defined by the user were used to provide an accumulative risk score for individuals in the target dataset, based on the alleles present at each SNP. The PRS calculated were compared between sEOAD cases and controls and the ability to successfully identify cases and controls was determined by Nagelkerke's R^2 value: the threshold which contains SNPs that produce the greatest Nagelkerke's R^2 value is the best-fit threshold for analysis.

PRSice was set to calculate polygenic risk scores for all individuals in the cohort at each P-value threshold in increments of one thousandth between 10^{-3} and 1. Uninformative SNPs determined to be in strong LD ($r^2 > 0.8$) within a linkage block when compared to the index SNP were removed. We tested a range of r^2 from 0.2 to 0.9 and selected 0.8 as this gave the best predictive model - Nagelkerke's value of 0.169 for $r^2 < 0.2$ versus 0.209 for $r^2 < 0.8$.

2.4 Statistical Analyses

Using the best-fit model, as identified by PRSice by the greatest Nagelkerke's R^2 value, the scores for each individual were analysed in SPSS to calculate the sensitivity and specificity of the model. The predictability of the model at correctly identifying cases and controls was calculated from the area under the receiver operating characteristic curve (AUC).

The results produced by PRSice were further analysed by decile scoring as carried out by Escott-Price *et al.* (2015). Decile scoring is an alternative to quartile and percentile scoring and provides further detail of trends in the data. Decile ranges were determined by segmenting the range of PRS into tenths and counting the number of cases and controls within each decile. Average scores of cases and controls within each decile were also calculated.

2.5 Polygenic Risk Score of the *APOE* locus

The *APOE* region is known to contain SNPs which affect risk of LOAD, the presence of the *APOE* $\epsilon 4$ allele correlates with a high risk of AD. To ensure coverage of the entire *APOE* locus with nearby genes, a 500kb region surrounding the *APOE* gene was isolated in the analysis by extracting the SNPs

within this region from the NeuroX dataset to produce an alternative target dataset (Karolchik *et al.*, 2004). The locus was identified as chr19:45,160,844-45,660,844 (GRCh37) (Kent *et al.*, 2002). This altered version of the target dataset, carrying genotype information for 198 SNPs (including rs7412 but not including rs429358 as this failed QC) within the *APOE* region, was also tested using PRSice to calculate risk scores.

Additional cohort information that is traditionally found to also be associated with AD risk; age, sex, and number of *APOE* ϵ 2 and/or ϵ 4 alleles were also integrated into the analysis. Logistic regression was performed on the *APOE* locus, PRS including the *APOE* locus, variables relevant to the analysis, and the combination of relevant variables with individual scores. Age was excluded as a variable as all cases were below age 65 whilst healthy controls were over age 65 at time of sampling. The AUC was calculated to determine whether accuracy of the model at predicting disease status improved with the inclusion of these demographic variables in the model. Hosmer-Lemeshow P-value is a result used to identify the goodness-of-fit of regression models; a non-significant value is considered a good model. Nagelkerke's R^2 value was calculated to compare models for the best fit, the greater the R^2 value, the better fit the model had for prediction.

3.0 Results

In this study sEOAD cases and controls were genotyped on the NeuroX array; the array results were clustered and subjected to QC to produce a target dataset. This, along with the base dataset provided by the IGAP consortium were used to generate PRS for all cases and controls using PRSice.

PRSice provides the Nagelkerke's R^2 scores produced at every P-value threshold tested and the number of SNPs used to calculate the scores. A total of 28,538 SNPs were common between the target dataset and the base dataset. The P-value threshold with the highest Nagelkerke's R^2 defines the best-fit for the dataset for identifying cases and controls. The best fit threshold used association data from 9,434 SNPs with a P-value ≤ 0.302 and produced the highest Nagelkerke's R^2 value of 0.209. A range of scores at different P-value thresholds with their corresponding R^2 values and number of SNPs included is presented in [Table 2](#).

The sensitivity and specificity of the best PRSice model was calculated in SPSS. Of the 408 cases in the NeuroX dataset, 59.1% were correctly identified as cases and 72.9% of the 436 controls were correctly identified as controls. The greatest predictive ability, AUC, of the PRS calculated by PRSice for this cohort was 72.9%. The value of Nagelkerke's R^2 calculated in SPSS, 0.209, was identical to the value obtained in PRSice, an indicator of reproductive power.

The average PRS for controls was $3.8E-04 \pm 6.75E-04$ and $5.8E-04 \pm 6.9E-04$ for cases - using an unpaired t-test on these PRS values gives a t-value of 12.33 with $p < 0.0001$. Decile scoring was also used to visualise the pattern of PRS distribution between cases and controls. Each decile covered one tenth of the score, however the proportion of individuals within each decile varied. The first four deciles have a majority of controls, with fewer controls having high PRS compared to cases. A PRS > 0.00045 would determine an individual to more likely be a case than control. The details of decile scoring are displayed in figure 1 along with the distribution of scores for cases and controls, with the identification of the average score at each decile presented in figure 2.

A 500kb region surrounding the *APOE* gene was identified and the SNPs within the locus were isolated in the target dataset; PRS was calculated for individuals using association data from the IGAP consortium. Of the 198 SNPs present on the NeuroX array within this region, 31 were common with the base dataset. The Nagelkerke's R^2 value corresponding with the best-fit threshold of $P \leq 0.001$ was 0.124 using association data from 28 SNPs; using only the *APOE* locus, cases and controls of AD can be predicted with an AUC of 65.2%. Linear regression was completed on the *APOE* locus dataset and compared to the PRS model as shown in figure 3. The *APOE* model identified controls with a specificity similar to the PRS model, calculated as 75.5% and 72.9% respectively; however, the ability to identify cases was not as accurate as the PRS model, with a sensitivity of 51.7% compared to 59.1%.

Variable information can also impact an individuals' risk of developing AD: identifying an individuals' *APOE* ϵ status is common in diagnosis, whilst gender needs to be controlled for whenever possible. A combination of these variables using logistic regression produced the best model for identifying controls, with a specificity of 76.8% and sensitivity of 56.9%, most likely due to the protective effect of the $\epsilon 2$ allele. However, combining these three variables ($\epsilon 2$, $\epsilon 4$ and Sex) with individuals' PRS produced a model with the best overall predictive ability of 75.5%; together with sensitivity of 64.5% and specificity of 73.1%. Results of logistic regression analysis for each risk-scoring model are depicted in figure 3.

4.0 Discussion

A cohort of sEOAD cases and controls were genotyped on the NeuroX array and this information was used to generate PRS in PRSice using SNP association data from the IGAP consortium as the training set. The resulting risk model could successfully recognise an individual to either have sEOAD or be a healthy control with 72.9% accuracy. The addition of variables (number of *APOE* ϵ 2 alleles, *APOE* ϵ 4 alleles and Sex) in logistic regression improved the predictability to 75.5%.

There was a significantly higher average PRS in cases than controls ($p < 0.0001$) with most individuals having a PRS above zero. Decile scoring showed most controls were within the lower deciles, with the absence of controls at the highest decile. For this analysis the base dataset we used was formed from LOAD cases rather than sEOAD, however we do not perceive this as an issue since the pathogenic mechanisms for both sEOAD and LOAD are likely shared (Barber *et al.*, 2017).

The *APOE* locus (500kb region centred on *APOE*) had a predictive accuracy of 65.2%, which confirms the high-risk contribution from known variants within this locus. Our analysis demonstrates that additional genetic variation across the rest of the genome also influences the risk of sEOAD. The NeuroX array that we have used genotypes SNPs from regions across the entire genome together with custom content which includes genes associated with several other neurological diseases including AD. These types of arrays provide a practical means to obtain greater accuracy of predictive ability in complex diseases.

The presence of controls with high PRS suggests that individuals can have SNPs that are associated with a greater risk of sEOAD but they may not develop AD. This would support the idea that in addition to risk variants there are uncharacterised protective variants in the genome that modify an individual's risk of getting the disease. The five controls present within the ninth decile had a high PRS; these individuals might have gone on to develop AD - the average age at death of these individuals was below eighty years. Additionally a high PRS could indicate risk for AD in later life or the risk of other neurological diseases that correlate with AD. Low PRS could be indicative of neuroprotection, however low scores were also be found in some of our sEOAD cases. Healthy controls with high PRS and cases with low PRS are possible indicators of missing heritability or as yet unknown environmental factors affecting the risk of developing AD.

The predictability of disease as estimated by the AUC derived from ϵ 2, ϵ 4 and Sex was 71.4%. The AUC for the best model included these variables but the addition of PRS increased the predictive ability by more than 3%. More extensive genotyping and additional information collected about individuals' lifestyles could further improve the predictability of AD risk. Further improvements of genetic-based prediction models could increase the predictability to the point where at-risk individuals are readily identified and potentially stratified using genetic testing.

The NeuroX array we have used in this study was the first version of an array specifically designed for neurological diseases. The custom content contributed 4,401 variants within the PRS threshold we have utilised, which accounted for 17.3% of the markers used to generate the scores. An increase in the number of markers to include a greater range of genetic variants associated with AD will undoubtedly lead to the generation of improved scores. Several of the loci identified more recently were not present on the first iteration of the NeuroX array. Increased coverage, such as that available from the latest version of the NeuroXchip version2 (Blauwendraat *et al.*, 2017), could provide additional information for generating more accurate risk scores thereby providing a better predictive model.

In the study performed by Escott-Price *et al.* (2015), an AUC of 78.2% was achieved using association data from 87,605 SNPs combined with covariate information for sex, age, and *APOE*. The study produced a set of scores with more variability, due to more SNPs in common between both datasets, although the indicator for a good model is ultimately determined by the Nagelkerke's R^2 value. A more diverse set of scores for AD could lead to the ability of identifying specific groups within the disease cohort, and introduce treatment plans according to the variants identified (Eusden *et al.*, 2015). In our study using a much-reduced number of pathologically confirmed sEOAD cases (n=408) we have obtained comparable PRS (AUC of 75.5%) to the original study of Escott-Price *et al.* (2015) generated for 3,049 LOAD cases and 1,554 controls. This demonstrates the increased power that can be realised using pathologically confirmed tissue in comparison to clinically defined samples. In a more recent study, Escott-Price *et al.* (2017a) used a modified approach to calculate the maximum possible predictive power (AUC_{max}) thereby improving the AUC produced previously from a value of 78.2% to 82%. More recently Escott-Price *et al.* (2017b) have performed PRS analysis on pathologically confirmed samples and found improved scores compared with the previous study on clinically diagnosed cases (Escott-Price *et al.* (2015)).

Other studies in AD using SNP scoring to generate risk scores have used SNPs with greater effect size as a means to reduce the number of SNPs required to calculate risk as discussed in the introduction. For example a genome-wide risk score has been calculated previously from the effect scores of just 31 SNPs and genotypes of the *APOE* $\epsilon 2$ and $\epsilon 4$ alleles (Desikan *et al.*, 2017). Using a model with tens of SNPs compared to thousands would provide a more cost-effective approach to screen for AD in individuals. Alternatively, identifying the variants which increase phenotypic risk in an individual using a risk score model could be used to form a more effective symptom-specific treatment plan. The ultimate driver will be the SNP set which provides the greatest prediction irrespective of SNP number.

Acknowledgements

The ARUK Consortium members are Peter Passmore, David Craig, Janet Johnston, Bernadette McGuinness, Stephen Todd, Reinhard Heun, Heike Kölsch, Patrick G. Kehoe, Emma R.L.C. Vardy, Nigel M. Hooper, Stuart Pickering-Brown, Julie Snowden, Anna Richardson, Matthew Jones, David Neary, Jennifer Harris, James Lowe, A. David Smith, Gordon Wilcock, Donald Warden, and Clive Holmes.

Jose Bras and Rita Guerreiro's work is funded by Fellowships from Alzheimer's Society. This work was partially funded by Alzheimer's Research UK, Alzheimer's Society and an anonymous donor.

We thank the International Genomics of Alzheimer's Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i-Select chips were funded by the French National Foundation on Alzheimer's disease and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2, and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant n° 503480), Alzheimer's Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIA AG081220 and AGES contract N01-AG-12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer's Association grant ADGC-10-196728.

This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, part of the Department of Health and Human Services; project Z01 AG000950.

References

Adams, H. H., R. F. de Bruijn, A. Hofman, A. G. Uitterlinden, C. M. van Duijn, M. W. Vernooij, P. J. Koudstaal and M. A. Ikram (2015). Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. *Alzheimer's Dementia* 11(11): 1277-1285

Ayers, K. L., Mirshahi, U. L., Wardeh, A. H., Murray, M. F., Hao, K., Glicksberg, B. S., Li, S., Carey, D. J. and Chen, R. (2016). A loss of function variant in CASP7 protects against Alzheimer's disease in homozygous APOE ϵ 4 allele carriers. *BMC Genomics*. 17: 445.

Barber, I., Braae, A., Clement, N., Patel, T., Guetta-Baranes, T., Brookes, K., Medway, C., Chappell, S., Guerreiro, R., Bras, J., Hernandez, D., Singleton, A., Hardy, J., Mann, D., ARUK Consortium and Morgan, K. (2017). Mutational analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. *Neurobiology of Aging*. 49. 215.e1-215.e8.

Basu, S., W. Pan, X. Shen and W. S. Oetting (2011). Multilocus association testing with penalized regression. *Genetic Epidemiology* 35(8): 755-765.

Blauwendraat, C., Faghri, F., Pihlstrom, L., Geiger, J. T., Elbaz, A., Lesage, S., Corvol, J., May, P., Ryten, M., Ferrari, R., Bras, J., Guerreiro, R., Williams, J., Sims, R., Lubbe, S., Hernandez, D. G., Mok, K. Y., Robak, L., Campbell, R. H., Rogaeva, E., Traynor, B. J., Chia, R., Chung, S. J., International Parkinson's Disease Genomics Consortium (IPDGC), COURAGE-PD Consortium, Hardy, J. A., Brice, A., Wood, N. W., Houlden, H., Shulman, J. M., Morris, H. R., Gasser, T., Krüger, R., Heutink, P., Sharma, M., Simón Sánchez, J., Nalls, M. A., Singleton, A. B., Scholz, S. W. (2017). *Neurobiology of Aging*.
<http://dx.doi.org/10.1016/j.neurobiolaging.2017.05.009>

Budson, A. and Kowall, N. (2011). *The Handbook of Alzheimer's Disease and Other Dementias*. Chichester, UK. Wiley-Blackwell. Preface XV-XV.

Bush, W. and Moore, J. (2012). Chapter 11: Genome-Wide Association Studies. *PLoS Computational Biology*. 8(12): e1002822.

Chapman, J. and J. Whittaker (2008). Analysis of multiple SNPs in a candidate gene or region. *Genetic Epidemiology* 32(6): 560-566.

Chouraki, V., C. Reitz, F. Maury, J. C. Bis, C. Bellenguez, L. Yu, J. Jakobsdottir, S. Mukherjee, H. H. Adams, S. H. Choi, E. B. Larson, A. Fitzpatrick, A. G. Uitterlinden, P. L. de Jager, A. Hofman, V. Gudnason, B. Vardarajan, C. Ibrahim-Verbaas, S. J. van der Lee, O. Lopez, J. F. Dartigues, C. Berr, P. Amouyel, D. A. Bennett, C. van Duijn, A. L. DeStefano, L. J. Launer, M. A. Ikram, P. K. Crane, J. C. Lambert, R. Mayeux and S. Seshadri (2016). Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. *J Alzheimer's Disease* 53(3): 921-932.

Desikan, R. S., Fan, C. C., Wang, Y., Schork, A. J., Cabral, H. J., Cupples, L. A., Thompson, W. K., Besser, L., Kukull, W. A., Holland, D., Chen, C., Brewer, J. B., Karow, D. S., Kauppi, K., Witoelar, A., Karch, C. M., Bonham, L. W., Yokoyama, J. S., Rosen, H. J., Miller, B. L., Dillion, W. P., Wilson, D. M., Hess, C. P., Pericak-Vance, M., Haines, J. L., Farrer, L. A., Mayeux, R., Hardy, J., Goate, A. M., Hyman, B. T., Schellenberg, G. D., McEvoy, L. K., Andreassen, O. A., Dale, A. M. (2017). Genetic assessment of age-associated Alzheimer's disease risk: Development and validation of a polygenic hazard score. *PLoS Medicine*. 14(3): e1002258.

Escott-Price, V., Sims, R., Bannister, C., Harold, D., Vronskaya, M., Majounie, E., Badarinarayan, N., GERAD/PARADES, IGAP consortia, Morgan, K., Passmore, P., Holmes, C., Powell, J., Brayne, C., Gill, M., Mead, S., Goate, A., Cruchaga, C., Lambert, J., van Duijn, C., Maier, W., Ramirez, A., Holmans, P.,

Jones, L., Hardy, J., Seshadri, S., Schellenberg, G. D., Amouyel and Williams, J. (2015). Common polygenic variation enhances risk prediction for Alzheimer's disease. *Brain*. 138: 3673-3684.

Escott-Price, V., Shoai, M., Pither, R., Williams, J., and Hardy, J. (2017a). Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease. *Neurobiology of Aging*. 49: 214e7-11.

Escott-Price, V., Myers, A. J., Huentelman, M., Hardy, J. (2017b). *Annals of Neurology*. 10.1002/ana.24999

Euesden, J., Lewis, C. and O'Reilly, P. (2015). PRSice: Polygenic Risk Score software. *Bioinformatics*. 31(9): 1466-1468.

Giri, M., Zhang, M. and Lü, Y. (2016). Genes associated with Alzheimer's disease: an overview and current status. *Clinical Interventions of Aging*. 11: 665-681

Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi, C., Kauwe J.S.K., Younkin S., Hazrati L., Collinge J., Pocock J., Lashley T., Williams J., Amouyel P., Goate A., Rademakers R., Morgan K., Powell J., George-Hislop P., Singleton A., Hardy J., and the Alzheimer Genetic Analysis Group, (2013). TREM2 variants in Alzheimer's disease. *The New England Journal of Medicine*, 368(2), 117–27.

Harrison, T. M., Z. Mahmood, E. P. Lau, A. M. Karacozoff, A. C. Burggren, G. W. Small and S. Y. Bookheimer (2016). An Alzheimer's Disease Genetic Risk Score Predicts Longitudinal Thinning of Hippocampal Complex Subregions in Healthy Older Adults. *eNeuro* 3(3).

Illumina. (2012). HumanExome BeadChips. Data Sheet: DNA Analysis. Available at: www.smd.qmul.ac.uk/gc/Services/InfiniumArrays/datasheet_humanexome_beadchips.pdf

Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., et al. (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. *The New England Journal of Medicine*, 368(2), 107–16.

Karolchik, D., Hinrichs, A. S., Furey, T. S., Roskin, K. M., Sugnet, C. W., Haussler, D. and Kent, W. J. (2004). The UCSC Table Browser data retrieval tool. *Nucleic Acids Research*. 32: D493-496.

Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M. and Haussler, D. The human genome browser at UCSC. (2002). *Genome Research*. 12(6): 996-1006.

Lambert, J. C., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., DeStafano, A. L., Bis, J. C., Beecham, G. W., Grenier-Boley, B., Russo, G., Thorton-Wells, T. A., Jones, N., Smith, A. V., Chouraki, V., Thomas, C., Ikram, M. A., Zelenika, D., Vardarajan, B. N., Kamatani, Y., Lin, C. F., Gerrish, A., Schmidt, H., Kunkle, B., Dunstan, M. L., Ruiz, A., Bihoreau, M.T., Choi, S.H., Reitz, C., Pasquier, F., Cruchaga, C., Craig, D., Amin, N., Berr, C., Lopez, O.L., De Jager, P. L., Deramecourt, V., Johnston, J. A., Evans, D., Lovestone, S., Letenneur, L., Morón, F. J., Rubinsztein, D. C., Eiriksdottir, G., Sleegers, K., Goate, A. M., Fiévet, N., Huentelman, M. W., Gill, M., Brown, K., Kamboh, M. I., Keller, L., Barberger-Gateau, P., McGuinness, B., Larson, E. B., Green, R., Myers, A. J., Dufouil, C., Todd, S., Wallon, D., Love, S., Rogaeva, E., Gallacher, J., St George-Hyslop, P., Clarimon, J., Lleo, A., Bayer, A., Tsuang, D. W., Yu, L., Tsolaki, M., Bossù, P., Spalletta, G., Proitsi, P., Collinge, J., Sorbi, S., Sanchez-Garcia, F., Fox, N. C., Hardy, J., Deniz Naranjo, M. C., Bosco, P., Clarke, R., Brayne, C., Galimberti, D., Mancuso, M., Matthews, F.; European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology, Moebus, S., Mecocci, P., Del Zompo, M., Maier,

W., Hampel, H., Pilotto, A., Bullido, M., Panza, F., Caffarra, P., Nacmias, B., Gilbert, J. R., Mayhaus, M., Lannefelt, L., Hakonarson, H., Pichler, S., Carrasquillo, M. M., Ingelsson, M., Beekly, D., Alvarez, V., Zou, F., Valladares, O., Younkin, S. G., Coto, E., Hamilton-Nelson, K. L., Gu, W., Razquin, C., Pastor, P., Mateo, I., Owen, M. J., Faber, K. M., Jonsson, P. V., Combarros, O., O'Donovan, M. C., Cantwell, L. B., Soininen, H., Blacker, D., Mead, S., Mosley, T. H. Jr., Bennett, D. A., Harris, T. B., Fratiglioni, L., Holmes, C., de Bruijn, R. F., Passmore, P., Montine, T. J., Bettens, K., Rotter, J. I., Brice, A., Morgan, K., Foroud, T. M., Kukull, W. A., Hannequin, D., Powell, J. F., Nalls, M. A., Ritchie, K., Lunetta, K. L., Kauwe, J. S., Boerwinkle, E., Riemenschneider, M., Boada, M., Hiltunen, M., Martin, E. R., Schmidt, R., Rujescu, D., Wang, L. S., Dartigues, J. F., Mayeux, R., Tzourio, C., Hofman, A., Nöthen, M. M., Graff, C., Psaty, B. M., Jones, L., Haines, J. L., Holmans, P. A., Lathrop, M., Pericak-Vance, M. A., Launer, L. J., Farrer, L. A., van Duijn, C. M., Van Broeckhoven, C., Moskvina, V., Seshadri, S., Williams, J., Schellenberg, G. D. and Amouyel, P. (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature Genetics*. 45(12): 1452-1458.

Liu, C., Kanekiyo, T., Xu, H. and Bu, G. (2013). Apolipoprotein E and Alzheimer's disease: risk, mechanisms, and therapy. *Nature Reviews Neurology*. 9(2): 106-118.

Liu, Y., Nyunoya, T., Leng, S., Belinsky, S. A., Tesfaigzi, Y., Bruse, S. (2013). Softwares and methods for estimating genetic ancestry in human populations. *Human Genomics*. 7(1): 1-7.

Logue, M. W., Schu, M., Vardarajan, B. N., Farrell, J., Bennett, D. A., Buxbaum, J. D., Byrd, G. S., Ertekin-Taner, N., Evans, D., Foroud, T., Goate, A., Graff-Radford, N. R., Kamboh, M. I., Kukull, W. A., Manly, J. J., Alzheimer's Disease Genetics Consortium, Haines, J. L., Mayeux, R., Pericak-Vance, M. A., Schellenberg, G. D., Lunetta, K. L., Baldwin, C. T., Fallin, M. D., and Farrer, L. A. (2014). Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. *Alzheimer's & Dementia*. 10 (6). Pages 609-618.

Lupton, M. K., L. Strike, N. K. Hansell, W. Wen, K. A. Mather, N. J. Armstrong, A. Thalamuthu, K. L. McMahon, G. I. de Zubicaray, A. A. Assareh, A. Simmons, P. Proitsi, J. F. Powell, G. W. Montgomery, D. P. Hibar, E. Westman, M. Tsolaki, I. Kloszewska, H. Soininen, P. Mecocci, B. Velas, S. Lovestone, H. Brodaty, D. Ames, J. N. Trollor, N. G. Martin, P. M. Thompson, P. S. Sachdev and M. J. Wright (2016). The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. *Neurobiology of Aging* 40: 68-77.

Marden, J. R., S. Walter, E. J. Tchetgen Tchetgen, I. Kawachi and M. M. Glymour (2014). Validation of a polygenic risk score for dementia in black and white individuals. *Brain Behaviour* 4(5): 687-697.

Marden, J. R., E. R. Mayeda, S. Walter, A. Vivot, E. J. Tchetgen Tchetgen, I. Kawachi and M. M. Glymour (2016). Using an Alzheimer Disease Polygenic Risk Score to Predict Memory Decline in Black and White Americans Over 14 Years of Follow-up. *Alzheimer Disease Associated Disorders* 30(3): 195-202.

Martiskainen, H., S. Helisalmi, J. Viswanathan, M. Kurki, A. Hall, S. K. Herukka, T. Sarajarvi, T. Natunen, K. M. Kurkinen, J. Huovinen, P. Makinen, M. Laitinen, A. M. Koivisto, K. M. Mattila, T. Lehtimaki, A. M. Remes, V. Leinonen, A. Haapasalo, H. Soininen and M. Hiltunen (2015). Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach. *J Alzheimer's Disease* 43(2): 565-573.

Morgan, A. R., S. Touchard, C. O'Hagan, R. Sims, E. Majounie, V. Escott-Price, L. Jones, J. Williams and B. P. Morgan (2017). The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer's Disease. *J Alzheimer's Disease* 56(1): 25-36.

Naj, A. C. and Schellenberg, G. D. (2016). Genomic Variants, Genes, and Pathways of Alzheimer's Disease: An Overview. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. 174: 5-26.

Nalls, M. A., Bras, J., Hernandez, D. G., Keller, M. F., Majounie, E., Renton, A. E., Saad, M., Jansen, I., Guerreiro, R., Lubbe, S., Plagnol, V., Gibbs, J. R., Schulte, C., Pankratz, N., Sutherland, M., Bertram, L., Lill, C. M., DeStefano, A. L., Faroud, T., Eriksson, N., Tung, J. Y., Edsall, C., Nichols, N., Brooks, J., Arepalli, S., Pilner, H., Letson, C., Heutink, P., Martinez, M., Gasser, T., Traynor, B. J., Wood, N., Hardy, J., Singleton, A. B. (2015). NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. *Neurobiology of Aging*. 36(3): 1605e7-12.

Pan, W., Y. M. Chen and P. Wei (2015). Testing for polygenic effects in genome-wide association studies. *Genetic Epidemiology* 39(4): 306-316.

Prince, M., Wimo, A., Guerchet, M., Ali, G., Wu, Y., Prina, M. (2015). World Alzheimer's Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost, and trends. *Alzheimer's Disease International*.

Purcell, S. M., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D., Maller, J., Sklar, P., de Bakker, P., Daly, M. and Sham, P. (2007). PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *The American Journal of Human Genetics*. 81(3): 559-575.

R Core Team. (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>.

Rodriguez-Rodriguez, E., P. Sanchez-Juan, J. L. Vazquez-Higuera, I. Mateo, A. Pozueta, J. Berciano, S. Cervantes, D. Alcolea, P. Martinez-Lage, J. Clarimon, A. Lleo, P. Pastor and O. Combarros (2013). Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. *J Neural Transmission* (Vienna) 120(5): 807-812.

Ruiz, A., Heilmann, S., Becker, T., Hernandez, I., Wagner, H., Thelen, M., Mauleon, A., Rosende-Roca, M., Bellenguez, C., Bis, J. C., Harold, D., Gerrish, A., Sims, R., Sotolongo-Grau, O., Espinosa, A., Alegret, M., Arrieta, J. L., Lacour, A., Leber, M., Becker, J., Lafuente, A., Ruiz, S., Vargas, L., Rodriguez, O., Ortega, G., Dominguez, M., IGAP, Mayeux, R., Haines, J. L., Pericak-Vance, M. A., Farrer, L. A., Schellenberg, G. D., Chouraki, V., Launer, L. J., van Duijn, C., Seshradi, S., Atunoz, C., Breteler, M. M., Serrano-Rios, M., Jessen, F., Tarraga, L., Nothen, M. M., Maier, W., Boada, M. and Ramirez, A. (2014). Follow-up of loci from the International Genomics of Alzheimer's Disease Project identifies TRIP4 as a novel susceptibility gene. *Translational Psychiatry*. 4 (2): e358.

Sabuncu, M. R., R. L. Buckner, J. W. Smoller, P. H. Lee, B. Fischl and R. A. Sperling (2012). The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. *Cerebral Cortex* 22(11): 2653-2661.

Sims, R., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., Kunkle, B. W., Boland, A., Raybould, R., Bis, J. C., Martin, E. R., Grenier-Boley, B., Heilmann-Heimbach, S., Chouraki, V., Kuzma, A. B., Sleegers, K., Vronskaya, M., Ruiz, A., Graham, R. R., O'Laso, R., Hoffmann, P., Grove, M. L., Vardarajan, B. N., Hiltunen, M., Nothen, M. M., White, C. C., Hamilton-Nelson, K. L., Epelbaum, J., Maier, W., Choi, S. H., Beecham, G. W., Dulary, C., Herms, S., Smith, A. V., Funk, C. C., Derbois, C., Forstner, A. J., Ahmad, S., Li, H., Bacq, D., Harold, D., Satizabal, C. L., Valladares, O., Squassina, A., Thomas, R., Brody, J. A., Qu, L., Sánchez-Juan, P., Morgan, T., Wolters, F. J., Zhao, Y., Garcia, F. S., Denning, N., Fornage, M., Malamon, J., Naranjo, M. C. D., Majounie, E., Mosley, T. H., Dombroski, B., Wallon, D., Lupton, M. K., Dupuis, J., Whitehead, P., Fratiglioni, L., Medway, C., Jian, X., Mukherjee,

S., Keller, L., Brown, K., Lin, H., Cantwell, L. B., Panza, F., McGuinness, B., Moreno-Grau, S., Burgess, J. D., Solfrizzi, V., Proitsi, P., Adams, H. H., Allen, M., Seripa, D., Pastor, P., Cupples, L. A., Price, N. D., Hannequin, D., Frank-García, A., Levy, D., Chakrabarty, P., Caffarra, P., Giegling, I., Beiser, A. S., Giedraitis, V., Hampel, H., Garcia, M. E., Wang, X., Lannfelt, L., Mecocci, P., Eiriksdottir, G., Crane, P. K., Pasquier, F., Boccardi, V., Henández, I., Barber, R. C., Scherer, M., Tarraga, L., Adams, P. M., Leber, M., Chen, Y., Albert, M. S., Riedel-Heller, S., Emilsson, V., Beekly, D., Braae, A., Schmidt, R., Blacker, D., Masullo, C., Schmidt, H., Doody, R. S., Spalletta, G., Jr, W. T. L., Fairchild, T. J., Bossù, P., Lopez, O. L., Frosch, M. P., Sacchinelli, E., Ghetti, B., Yang, Q., Huebinger, R. M., Jessen, F., Li, S., Kamboh, M. I., Morris, J., Sotolongo-Grau, O., Katz, M. J., Corcoran, C., Dunstan, M., Braddel, A., Thomas, C., Meggy, A., Marshall, R., Gerrish, A., Chapman, J., Aguilar, M., Taylor, S., Hill, M., Fairén, M. D., Hodges, A., Vellas, B., Soininen, H., Kloszewska, I., Daniilidou, M., Uphill, J., Patel, Y., Hughes, J. T., Lord, J., Turton, J., Hartmann, A. M., Cecchetti, R., Fenoglio, C., Serpente, M., Arcaro, M., Caltagirone, C., Orfei, M. D., Ciaramella, A., Pichler, S., Mayhaus, M., Gu, W., Lleó, A., Fortea, J., Blesa, R., Barber, I. S., Brookes, K., Cupidi, C., Maletta, R. G., Carrell, D., Sorbi, S., Moebus, S., Urbano, M., Pilotto, A., Kornhuber, J., Bosco, P., Todd, S., Craig, D., Johnston, J., Gill, M., Lawlor, B., Lynch, A., Fox, N. C., Hardy, J.; ARUK Consortium, Albin, R. L., Apostolova, L. G., Arnold, S. E., Asthana, S., Atwood, C. S., Baldwin, C. T., Barnes, L. L., Barral, S., Beach, T. G., Becker, J. T., Bigio, E. H., Bird, T. D., Boeve, B. F., Bowen, J. D., Boxer, A., Burke, J. R., Burns, J. M., Buxbaum, J. D., Cairns, N. J., Cao, C., Carlson, C. S., Carlsson, C. M., Carney, R. M., Carrasquillo, M. M., Carroll, S. L., Diaz, C. C., Chui, H. C., Clark, D. G., Cribbs, D. H., Crocco, E. A., DeCarli, C., Dick, M., Duara, R., Evans, D. A., Faber, K. M., Fallon, K. B., Fardo, D. W., Farlow, M. R., Ferris, S., Foroud, T. M., Galasko, D. R., Gearing, M., Geschwind, D. H., Gilbert, J. R., Graff-Radford, N. R., Green, R. C., Growdon, J. H., Hamilton, R. L., Harrell, L. E., Honig, L. S., Huentelman, M. J., Hulette, C. M., Hyman, B. T., Jarvik, G. P., Abner, E., Jin, L. W., Jun, G., Karydas, A., Kaye, J. A., Kim, R., Kowall, N. W., Kramer, J. H., LaFerla, F. M., Lah, J. J., Leverenz, J. B., Levey, A. I., Li, G., Lieberman, A. P., Lunetta, K. L., Lyketsos, C. G., Marson, D. C., Martiniuk, F., Mash, D. C., Masliah, E., McCormick, W. C., McCurry, S. M., McDavid, A. N., McKee, A. C., Mesulam, M., Miller, B. L., Miller, C. A., Miller, J. W., Morris, J. C., Murrell, J. R., Myers, A. J., O'Bryant, S., Olichney, J. M., Pankratz, V. S., Parisi, J. E., Paulson, H. L., Perry, W., Peskind, E., Pierce, A., Poon, W. W., Potter, H., Quinn, J. F., Raj, A., Raskind, M., Reisberg, B., Reitz, C., Ringman, J. M., Roberson, E. D., Rogaeva, E., Rosen, H. J., Rosenberg, R. N., Sager, M. A., Saykin, A. J., Schneider, J. A., Schneider, L. S., Seeley, W. W., Smith, A. G., Sonnen, J. A., Spina, S., Stern, R. A., Swerdlow, R. H., Tanzi, R. E., Thornton-Wells, T. A., Trojanowski, J. Q., Troncoso, J. C., Van Deerlin, V. M., Van Eldik, L. J., Vinters, H. V., Vonsattel, J. P., Weintraub, S., Welsh-Bohmer, K. A., Wilhelmsen, K. C., Williamson, J., Wingo, T. S., Woltjer, R. L., Wright, C. B., Yu, C. E., Yu, L., Garzia, F., Golamally, F., Septier, G., Engelborghs, S., Vandenberghe, R., De Deyn, P. P., Fernandez, C. M., Benito, Y. A., Thonberg, H., Forsell, C., Lilius, L., Kinhult-Ståhlbom, A., Kilander, L., Brundin, R., Concari, L., Helisalmi, S., Koivisto, A. M., Haapasalo, A., Dermecourt, V., Fievet, N., Hanon, O., Dufouil, C., Brice, A., Ritchie, K., Dubois, B., Himali, J. J., Keene, C. D., Tschanz, J., Fitzpatrick, A. L., Kukull, W. A., Norton, M., Aspelund, T., Larson, E. B., Munger, R., Rotter, J. I., Lipton, R. B., Bullido, M. J., Hofman, A., Montine, T. J., Coto, E., Boerwinkle, E., Petersen, R. C., Alvarez, V., Rivadeneira, F., Reiman, E. M., Gallo, M., O'Donnell, C. J., Reisch, J. S., Bruni, A. C., Royall, D. R., Dichgans, M., Sano, M., Galimberti, D., St George-Hyslop, P., Scarpini, E., Tsuang, D. W., Mancuso, M., Bonuccelli, U., Winslow, A. R., Daniele, A., Wu, C. K.; GERAD/PERADES, CHARGE, ADGC, EADI, Peters, O., Nacmias, B., Riemenschneider, M., Heun, R., Brayne, C., Rubinsztein, D. C., Bras, J., Guerreiro, R., Al-Chalabi, A., Shaw, C. E., Collinge, J., Mann, D., Tsolaki, M., Clarimón, J., Sussams, R., Lovestone, S., O'Donovan, M. C., Owen, M. J., Behrens, T. W., Mead, S., Goate, A. M., Uitterlinden, A. G., Holmes, C., Cruchaga, C., Ingelsson, M., Bennett, D. A., Powell, J., Golde, T. E., Graff, C., De Jager, P. L., Morgan, K., Ertekin-Taner, N., Combarros, O., Psaty, B. M., Passmore, P., Younkin, S. G., Berr, C., Gudnason, V., Rujescu, D., Dickson, D. W., Dartigues, J. F., DeStefano, A. L., Ortega-Cubero, S.,

Hakonarson, H., Campion, D., Boada, M., Kauwe, J. K., Farrer, L. A., van Broeckhoven, C., Ikram, M. A., Jones, L., Haines, J. L., Tzourio, C., Launer, L. J., Escott-Price V., Mayeux, R., Deleuze, J. F., Amin, N., Holmans, P. A., Pericak-Vance, M. A., Amouyel, P., van Duijn, C. M., Ramirez, A., Wang, L. S., Lambert, J. C., Seshadri S., Williams J. and Schellenberg G. D. (2017). Rare coding variants in *PLCG2*, *ABI3* and *TREM2* implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature Genetics*. 49: 1373-1384.

Sleegers, K., K. Bettens, A. De Roeck, C. Van Cauwenberghe, E. Cuyvers, J. Verheijen, H. Struyfs, J. Van Dongen, S. Vermeulen, S. Engelborghs, M. Vandenbulcke, R. Vandenberghe, P. P. De Deyn and C. Van Broeckhoven (2015). A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Abeta42." *Alzheimer's Dementia* 11(12): 1452-1460.

Verhaaren, B. F., M. W. Vernooij, P. J. Koudstaal, A. G. Uitterlinden, C. M. van Duijn, A. Hofman, M. M. Breteler and M. A. Ikram (2013). Alzheimer's disease genes and cognition in the nondemented general population. *Biol Psychiatry* 73(5): 429-434.

Wingo, T. S., Lah, J. J., Levey, A. I. and Cutler, D. J. (2012). Autosomal Recessive Causes Likely in Early-Onset Alzheimer's Disease. *Archives of Neurology*. 69: 59.

Xiao, Q., Z. J. Liu, S. Tao, Y. M. Sun, D. Jiang, H. L. Li, H. Chen, X. Liu, B. Lapin, C. H. Wang, S. L. Zheng, J. Xu and Z. Y. Wu (2015). Risk prediction for sporadic Alzheimer's disease using genetic risk score in the Han Chinese population. *Oncotarget* 6(35): 36955-36964.

Yokoyama, J. S., L. W. Bonham, R. L. Sears, E. Klein, A. Karydas, J. H. Kramer, B. L. Miller and G. Coppola (2015). Decision tree analysis of genetic risk for clinically heterogeneous Alzheimer's disease. *BMC Neurology* 15: 47.

Legends

Figure 1 – Proportion of diagnosed sEOAD cases and controls at each decile determined by range of score.

The figure breaks down the range of PRS into deciles. The range of scores which make up each decile are depicted as well as the number of cases and controls, and the percentage of individuals which fall into each decile. Controls are right-skewed whilst cases demonstrate left skewness. These figures were produced from PRS of 408 sEOAD cases and 436 controls. The embedded table lists the decile ranges with the number of cases and controls in each decile along with the proportion of the cohort which make up each decile.

Figure 2 – Distribution of polygenic risk score amongst sEOAD cases and controls with average scores at each decile.

The range of PRS obtained for cases and controls are distributed into deciles. The range of coverage of each decile is shown in the bar plot together with the proportion of cases and controls which make up each decile. The average scores for all cases and controls are indicated by the thick bar whilst the short horizontal bars show PRS for each individual. Average scores at each decile are indicated as hollow circles for cases and filled circles for controls.

Figure 3 – Results of logistic regression with an area under the receiver operating characteristic curve (AUC) for alternative risk scoring models in sEOAD.

For this analysis, the APOE locus was defined as a 500kb region surrounding the APOE gene and the scores produced by PRSice for this model are based on the SNPs within that region; PRS represents the score produced for all SNPs present on both the NeuroX array and in the base dataset. The relevant variables included sex together with the number of APOE ϵ 2 allele and/or APOE ϵ 4 allele. As shown in the table a non-significant Hosmer-Lemeshow P-value suggests the model is suitable for using as a predictive tool. Nagelkerke's R^2 can also be used to identify the best model for risk prediction, the higher the value of R^2 the greater the predictive accuracy of each model. This approach identified Sex, E2, E4 + PRS as the best model for calculating risk in our sEOAD cohort as the largest AUC value is produced from the combination of variables.

Table 1**A**

Centre	N	Mean age at onset	Females (%)	APOE ε4+ (%)	APOE ε4ε4 (%)
Bristol	21	53.3	11 (52.4)	10 (47.6)	3 (14.3)
Manchester	328	57.1	152 (46.3)	194 (59.1)	47 (14.3)
Nottingham	26	58.2	12 (46.2)	11 (42.3)	1 (3.8)
Oxford	33	55.6	19 (57.6)	19 (57.6)	3 (9.1)
All sEOAD Cases	408	56.8	194 (47.5)	234 (57.4)	54 (13.2)

B

Centre	N	Mean age at death	Females (%)	APOE ε4+ (%)	APOE ε4ε4 (%)
UCL	436	77.2	256 (58.7)	104 (23.9)	9 (2.2)

Table 2

P-value threshold	Nagelkerke's R²	Number of SNPs
≤0.001	0.149	141
≤0.002	0.154	203
≤0.005	0.163	355
≤0.010	0.172	546
≤0.020	0.176	930
≤0.050	0.181	2,022
≤0.100	0.193	3,595
≤0.200	0.204	6,545
≤0.302	0.209	9,434
≤0.500	0.207	14,995
≤1.00	0.203	28,538

Legends

Table 1 – Demographics of the sEOAD and controls cohort.

The sEOAD cases were recruited from four centres within the UK, the number of individuals from each centre is outlined above. All cases had a documented or calculated age at onset below 65 years. The number of females from each centre is recorded with the percentage per centre together with the percentage of individuals from each centre harbouring at least one APOE $\epsilon 4$ allele ($\epsilon 4+$) along with the number and percentage of individuals from each centre with the $\epsilon 4\epsilon 4$ genotype. (B) All controls were recruited from a single centre in the UK (UCL, London), the number of individuals is given above. The mean age at death for controls is given with the number and proportion of females. The number of individuals harbouring at least one APOE $\epsilon 4$ allele and the number and proportion of controls with the $\epsilon 4\epsilon 4$ genotype is also included.

Table 2 – Nagelkerke's R^2 values at varying p-value thresholds

The table lists some of the P-value thresholds tested by PRSice and their corresponding Nagelkerke's R^2 value, along with the number of SNPs used in calculating PRS. A total of 28,438 SNPs were common between the NeuroX array and the SNPs collected by the IGAP consortium. The greatest R^2 value was at the threshold of $P \leq 0.302$, and used variant information from 9,434 SNPs.